| |
| |
|
| Insider
Information: |
Rowland Charles A Jr |
| Relationship: |
|
| City: |
Chadds Ford |
| State: |
PA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
8 |
|
| Direct
Shares |
607,545 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$2,535,218 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
607,545 |
|
|
| Total
Value |
$2,535,218 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
3
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-3.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -48.6%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Viropharma Inc |
VPHM |
VP, Chief Financial Of... |
2014-01-24 |
0 |
2008-11-03 |
0 |
Premium* |
|
|
Endo Health Solutions Inc |
ENDP |
EVP, CFO & Treasurer |
2008-02-21 |
6,699 |
2008-02-21 |
0 |
Premium* |
|
|
DNIB Upwind Inc |
BIND |
Director |
2016-08-26 |
15,000 |
2016-08-26 |
0 |
Premium* |
|
|
Viking Therapeutics, Inc. |
VKTX |
Director |
2023-05-16 |
30,000 |
2018-05-29 |
0 |
Premium* |
|
|
Nabriva Therapeutics AG |
NBRV |
Director |
2022-08-01 |
15,277 |
2018-12-24 |
0 |
Premium* |
|
|
Blueprint Medicines Corp |
BPMC |
Director |
2021-06-02 |
5,812 |
2019-06-20 |
0 |
Premium* |
|
|
Orchard Therapeutics Plc |
ORTX |
|
2024-01-24 |
0 |
|
0 |
Premium* |
|
|
Generation Bio Co. |
GBIO |
|
2023-12-04 |
534,757 |
2020-06-16 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
50 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
• • – |
2014-01-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(48,878) |
0 |
0 |
- |
|
| VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
• • – |
2014-01-24 |
4 |
D |
$50.00 |
$4,351,300 |
D/D |
(87,026) |
0 |
0 |
- |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2019-06-20 |
4 |
S |
$94.83 |
$1,124,462 |
D/D |
(11,818) |
0 |
0 |
- |
|
| ORTX |
Orchard Therapeutics Plc |
|
– • – |
2024-01-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(12,294) |
0 |
0 |
- |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2020-06-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,312 |
1,312 |
0 |
- |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2020-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,250 |
3,562 |
0 |
- |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2020-11-02 |
4 |
S |
$99.11 |
$443,815 |
D/D |
(4,478) |
3,562 |
0 |
% |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2020-11-03 |
4 |
S |
$95.97 |
$545,196 |
D/D |
(5,522) |
3,562 |
0 |
% |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2020-12-17 |
4 |
S |
$117.82 |
$1,285,298 |
D/D |
(10,909) |
3,562 |
0 |
% |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,250 |
5,812 |
0 |
- |
|
| ENDP |
Endo Health Solutions Inc |
EVP, CFO & Treasurer |
• – – |
2008-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
6,699 |
6,699 |
0 |
- |
|
| VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
• – – |
2008-11-03 |
4 |
B |
$12.77 |
$102,160 |
D/D |
8,000 |
8,000 |
2.74 |
- |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2020-11-02 |
4 |
OE |
$9.46 |
$42,362 |
D/D |
4,478 |
8,040 |
0 |
- |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2020-11-03 |
4 |
OE |
$9.46 |
$52,238 |
D/D |
5,522 |
9,084 |
0 |
- |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2019-06-20 |
4 |
OE |
$9.46 |
$111,798 |
D/D |
11,818 |
11,818 |
0 |
- |
|
| ORTX |
Orchard Therapeutics Plc |
Director |
– • – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,294 |
|
- |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2020-12-17 |
4 |
OE |
$19.53 |
$213,053 |
D/D |
10,909 |
14,471 |
0 |
- |
|
| BIND |
DNIB Upwind Inc |
Director |
– • – |
2016-08-26 |
4 |
OE |
$0.44 |
$6,600 |
D/D |
15,000 |
15,000 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Director |
– • – |
2022-08-01 |
4 |
S |
$0.18 |
$1,487 |
D/D |
(8,496) |
15,277 |
0 |
- |
|
| VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
• – – |
2012-03-01 |
4 |
S |
$32.11 |
$2,657,631 |
D/D |
(82,750) |
17,125 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Director |
– • – |
2021-08-02 |
4 |
S |
$1.20 |
$932 |
D/D |
(777) |
23,773 |
0 |
- |
|
| VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
• – – |
2009-02-26 |
4 |
B |
$4.78 |
$76,522 |
D/D |
16,000 |
24,000 |
2.74 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Director |
– • – |
2021-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
17,500 |
24,550 |
0 |
- |
|
| VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
• – – |
2011-03-14 |
4 |
S |
$18.55 |
$649,950 |
D/D |
(35,000) |
28,496 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Director |
– • – |
2018-05-29 |
4 |
B |
$5.16 |
$154,800 |
D/D |
30,000 |
30,000 |
2.39 |
- |
|
50 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
